Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells

Thrombosis and Haemostasis

Volumn 105, Issue 6, 2011, Pages 999-1009

  Lin, Joellen H H ^a   Garand, Mathieu ^b   Zagorac, Branislava ^b   Schadinger, Steven L ^a   Scipione, Corey ^b   Koschinsky, Marlys L ^b   Boffa, Michael B ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

Gene expression; Megakaryocytes; Monocytes macrophages; Platelets; Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

MESSENGER RNA; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXON; GENOTYPE; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MEGAKARYOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

BLOOD COAGULATION; ENDOTHELIAL CELLS; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HEMOSTASIS; HEP G2 CELLS; HUMANS; INFLAMMATION; MACROPHAGES; MEGAKARYOCYTE PROGENITOR CELLS; MEMBRANE GLYCOPROTEINS; VASCULAR DISEASES;

EID: 79958177151     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-06-0413     Document Type: Article

References (52)

1. Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124: 33S-39S.
2. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
3. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
4. Mao SS, Cooper CM, Wood T, et al. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-35052.
5. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
6. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
7. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-939.
8. Hendriks D, Scharpé S, van Sande M, et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-285.
9. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-13339.
10. Schneider M, Brufatto N, Neill E, et al. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004; 279: 13340-13345.
11. Frère C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373-379.
12. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
13. Meltzer ME, Lisman T, de Groot PG et al. Venous thrombosis risk associated with plasma hypofibirnolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
14. Eichinger S, Schönauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
15. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombinactivatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3: 2211-2218.
16. Santamaría A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-2391.
17. Rooth E, Wallen H, Antovic A et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coag Fibrinolysis 2007; 18: 365-370.
18. Ladenvall C, Gils A, Jood K et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27: 955-962.
19. de Bruijen EL, Gils A, Guimarães AH et al. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 2009; 7: 919-927.
20. Trégouet DA, Schnabel R, Alessi MC et al. Activated thrombin activatable fibrnolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study. J Thromb Haemost 2009; 7: 49-57.
21. Campbell WD, Lazoura E, Okada N, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
22. Hendriks D, Wang W, van Sande M, et al. Human serum carboxypeptidase U: a new kininase? Agents Actions Suppl 1992; 38: 407-413
23. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
24. Leung LL, Myles T, Nishimura T, et al. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45: 4080-4083.
25. Du XY, Zabel BA, Myles T, et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284: 751-758.
26. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-670.
27. Boffa MB, Reid TS, Joo E, et al. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 6547-6558.
28. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-4846.
29. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
30. Aubert H, Frère C, Aillaud MF, et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791-797.
31. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.
32. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
33. Greenberg SM, Rosenthal DS, Greeley TA, et al. Characterization of a new megakaryocytic cell line: the Dami cell. Blood 1988; 72: 1968-1977.
34. Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-176.
35. Zhao SP, Deng P, Huang H et al. Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance. 2005; Clinical Chemistry, 51: 2170-2173.
36. Maret D, Boffa MB, Brien DF, et al. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. J Thromb Haemost 2004; 2: 1969-1979.
37. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 59-74.
38. Boffa MB, Wang W, Bajzar L, et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-2135.
39. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-1127.
40. Kim PY, Foley J, Hsu G, et al. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2008; 372: 32-40.
41. Isakari Y, Sogo S, Ishida T, et al. Gene expression analysis during platelet-like particle production in phorbol myristate acetate-treated MEG-01 cells. Biol Pharm Bull 2009; 32: 354-358.
42. Perez A, Thuillard JL, Bentzen CL, et al. Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell Biol Toxicol 2003; 19: 95-105.
43. Fugman DA, Witte DP, Jones CL, et al. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood 1990; 75: 1252-1261.
44. Briquet-Laugier V, El Golli N, Nurden P, et al. Thrombopoietin-induced Dami cells as a model for alpha-granule biogenesis. Platelets 2004; 15: 341-344.
45. Schadinger SL, Lin JHH, Garand M et al. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 2010; 8: 2523-2529.
46. Auwerx J. The human leukemia cell line, THP-1: a multifecetted model for the study of monocyte-macrophage differentiation. Experentia 1991; 47: 22-31.
47. te Velde EA, Wagenaar GT, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-2096.
48. Swaisgood CM, Schmitt D, Eaton D, et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-1282.
49. Verbon A, Meijers JC, Spek CA, et al. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003; 187: 55-61.
50. Emonts M, de Bruijne EL, Guimarães AH, et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 6: 268-276.
51. Bengtson SH, Sandén C, Mörgelin M, et al. Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/ kinin system. J Innate Immun 2008; 1: 18-28.
52. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.